{"transactions":[{"id":4628437,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":93.91,"value":9391.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":537540,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628436,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":4990,"price":93.37,"value":465916.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.89 to $93.80, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":537640,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628435,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3989,"price":92.31,"value":368224.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.87 to $92.86, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":542630,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628434,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2638,"price":91.49,"value":241350.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.85 to $91.84, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":546619,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628433,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":2683,"price":90.1,"value":241738.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.80 to $90.76, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":549257,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4628432,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-03T01:29:57.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":89.14,"value":53484.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.52, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 29,078 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":551940,"source":{"system":"sec-edgar","filing":"0001636282-26-000118","document":"wk-form4_1790990994.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000118/wk-form4_1790990994.xml","form_type":"4"}},{"id":4030,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":400,"price":89.07,"value":35628.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":552540,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":4029,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":3700,"price":88.06,"value":325822.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.68 to $88.67, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":552940,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":4028,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":8400,"price":87.15,"value":732060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.67 to $87.65, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":556640,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":4027,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-04T01:33:05.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":86.36,"value":215900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.67 to $86.66, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":565040,"source":{"system":"sec-edgar","filing":"0001636282-26-000107","document":"wk-form4_1788485583.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000163628226000107/wk-form4_1788485583.xml","form_type":"4"}},{"id":695278,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":16,"price":97.46,"value":1559.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.46 to $97.47, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":567540,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695277,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":1392,"price":96.82,"value":134773.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.45 to $97.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":567556,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695276,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":5635,"price":95.93,"value":540565.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.45 to $96.44, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":568948,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695275,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":7157,"price":95.1,"value":680630.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.44 to $95.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":574583,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":695274,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-06T01:31:09.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":800,"price":93.97,"value":75176.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.42 to $94.33, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 58,108 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":581740,"source":{"system":"sec-edgar","filing":"0001636282-26-000099","document":"wk-form4_1785979866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000099/wk-form4_1785979866.xml","form_type":"4"}},{"id":717168,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:32:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":590,"price":88.91,"value":52456.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.86 to $88.98, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":582540,"source":{"system":"sec-edgar","filing":"0001636282-26-000086","document":"wk-form4_1783042321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000086/wk-form4_1783042321.xml","form_type":"4"}},{"id":717167,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:32:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":4234,"price":88.12,"value":373100.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.82 to $88.75, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":583130,"source":{"system":"sec-edgar","filing":"0001636282-26-000086","document":"wk-form4_1783042321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000086/wk-form4_1783042321.xml","form_type":"4"}},{"id":717166,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-03T01:32:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":10176,"price":87.44,"value":889789.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.82 to $87.81, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 72,623 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":587364,"source":{"system":"sec-edgar","filing":"0001636282-26-000086","document":"wk-form4_1783042321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000086/wk-form4_1783042321.xml","form_type":"4"}},{"id":750827,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:31:11.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3294,"price":71.38,"value":235125.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":597540,"source":{"system":"sec-edgar","filing":"0001636282-26-000077","document":"wk-form4_1780536669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000077/wk-form4_1780536669.xml","form_type":"4"}},{"id":750826,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:31:11.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":8149,"price":70.5,"value":574504.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":600834,"source":{"system":"sec-edgar","filing":"0001636282-26-000077","document":"wk-form4_1780536669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000077/wk-form4_1780536669.xml","form_type":"4"}},{"id":750825,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-04T01:31:11.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3557,"price":69.4,"value":246855.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":608983,"source":{"system":"sec-edgar","filing":"0001636282-26-000077","document":"wk-form4_1780536669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000077/wk-form4_1780536669.xml","form_type":"4"}},{"id":795269,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:11.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":300,"price":74.96,"value":22488.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.95 to $74.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":612540,"source":{"system":"sec-edgar","filing":"0001758363-26-000009","document":"wk-form4_1777685648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000009/wk-form4_1777685648.xml","form_type":"4"}},{"id":795268,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:11.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1700,"price":74.23,"value":126191.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.95 to $74.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":612840,"source":{"system":"sec-edgar","filing":"0001758363-26-000009","document":"wk-form4_1777685648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000009/wk-form4_1777685648.xml","form_type":"4"}},{"id":795267,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:11.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":3100,"price":73.14,"value":226734.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.75 to $73.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":614540,"source":{"system":"sec-edgar","filing":"0001758363-26-000009","document":"wk-form4_1777685648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000009/wk-form4_1777685648.xml","form_type":"4"}},{"id":795266,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:11.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":71.76,"value":71760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.41 to $72.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":617640,"source":{"system":"sec-edgar","filing":"0001758363-26-000009","document":"wk-form4_1777685648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000009/wk-form4_1777685648.xml","form_type":"4"}},{"id":795265,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:11.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":3600,"price":70.77,"value":254772.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $71.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":618640,"source":{"system":"sec-edgar","filing":"0001758363-26-000009","document":"wk-form4_1777685648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000009/wk-form4_1777685648.xml","form_type":"4"}},{"id":795264,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-02T01:34:11.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5300,"price":69.54,"value":368562.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.25 to $70.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 101,653 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":622240,"source":{"system":"sec-edgar","filing":"0001758363-26-000009","document":"wk-form4_1777685648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000009/wk-form4_1777685648.xml","form_type":"4"}},{"id":815594,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:30:43.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2656,"price":49.92,"value":132587.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.64 to $50.50, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":627540,"source":{"system":"sec-edgar","filing":"0001758363-26-000007","document":"wk-form4_1775266241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000007/wk-form4_1775266241.xml","form_type":"4"}},{"id":815593,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-04T01:30:43.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":12344,"price":49.2,"value":607324.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.64 to $49.63, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":630196,"source":{"system":"sec-edgar","filing":"0001758363-26-000007","document":"wk-form4_1775266241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000007/wk-form4_1775266241.xml","form_type":"4"}},{"id":827994,"issuer":{"id":4602,"kind":"organization","name":"Damora Therapeutics, Inc.","symbol":"DMRA"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T22:08:21.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":37313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":37313,"derivative":{"exercise_price":23.05,"expiration_date":"2036-03-23","underlying":"Common Stock","underlying_shares":37313},"source":{"system":"sec-edgar","filing":"0001193125-26-124483","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1758363/000119312526124483/ownership.xml","form_type":"4"}},{"id":865058,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:31:30.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":9100,"price":42.49,"value":386659.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.23 to $42.93, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":642540,"source":{"system":"sec-edgar","filing":"0001636282-26-000026","document":"wk-form4_1772591487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000026/wk-form4_1772591487.xml","form_type":"4"}},{"id":865057,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-04T02:31:30.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5900,"price":41.73,"value":246207.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.23 to $42.19, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 130,683 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":651640,"source":{"system":"sec-edgar","filing":"0001636282-26-000026","document":"wk-form4_1772591487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000026/wk-form4_1772591487.xml","form_type":"4"}},{"id":919021,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-05T02:33:37.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":14043,"price":32.87,"value":461593.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.48 to $33.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":657540,"source":{"system":"sec-edgar","filing":"0001758363-26-000005","document":"wk-form4_1770258815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000005/wk-form4_1770258815.xml","form_type":"4"}},{"id":919020,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-05T02:33:37.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":957,"price":31.82,"value":30451.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.42 to $32.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 633 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024."}],"balance_after":671583,"source":{"system":"sec-edgar","filing":"0001758363-26-000005","document":"wk-form4_1770258815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000005/wk-form4_1770258815.xml","form_type":"4"}},{"id":939901,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-14T02:27:08.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":528000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 528,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":528000,"derivative":{"exercise_price":30.61,"expiration_date":"2036-01-09","underlying":"Common Stock","underlying_shares":528000},"source":{"system":"sec-edgar","filing":"0001636282-26-000003","document":"wk-form4_1768357625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000003/wk-form4_1768357625.xml","form_type":"4"}},{"id":945655,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-07T02:36:32.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":100,"price":32.39,"value":3239.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $32.41, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":671907,"source":{"system":"sec-edgar","filing":"0001758363-26-000002","document":"wk-form4_1767753388.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000002/wk-form4_1767753388.xml","form_type":"4"}},{"id":945654,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-07T02:36:32.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":2191,"price":31.79,"value":69651.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.29 to $32.28, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":672007,"source":{"system":"sec-edgar","filing":"0001758363-26-000002","document":"wk-form4_1767753388.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000002/wk-form4_1767753388.xml","form_type":"4"}},{"id":945653,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-07T02:36:32.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":12709,"price":30.47,"value":387243.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.20 to $31.00, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 159,713 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":674198,"source":{"system":"sec-edgar","filing":"0001758363-26-000002","document":"wk-form4_1767753388.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836326000002/wk-form4_1767753388.xml","form_type":"4"}},{"id":981072,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-04T02:52:20.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":4005,"price":29.83,"value":119469.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.47 to $30.43, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 174,228 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":686907,"source":{"system":"sec-edgar","filing":"0001758363-25-000003","document":"wk-form4_1764816738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836325000003/wk-form4_1764816738.xml","form_type":"4"}},{"id":981071,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-04T02:52:20.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":10995,"price":28.73,"value":315886.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.45 to $29.44, inclusive. The Reporting Person undertakes to provide to\nthe Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price\nwithin the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 174,228 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":690912,"source":{"system":"sec-edgar","filing":"0001758363-25-000003","document":"wk-form4_1764816738.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000175836325000003/wk-form4_1764816738.xml","form_type":"4"}},{"id":1006569,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-06T02:15:05.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":16845,"price":23.66,"value":398552.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.51 to $24.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 188,743 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":701907,"source":{"system":"sec-edgar","filing":"0001636282-25-000106","document":"wk-form4_1762395302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000106/wk-form4_1762395302.xml","form_type":"4"}},{"id":1006568,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-06T02:15:05.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":28155,"price":23.13,"value":651225.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.51 to $23.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 188,743 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":718752,"source":{"system":"sec-edgar","filing":"0001636282-25-000106","document":"wk-form4_1762395302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000106/wk-form4_1762395302.xml","form_type":"4"}},{"id":1126284,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-03T20:13:14.000Z","date":"2025-06-02","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from June 2, 2025."}],"balance_after":17500,"derivative":{"exercise_price":11.77,"expiration_date":"2035-06-01","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001062993-25-010824","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000106299325010824/form4.xml","form_type":"4"}},{"id":1299663,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-17T21:35:13.000Z","date":"2025-01-15","kind":"grant","planned":false,"acquired":true,"shares":370000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 370,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":370000,"derivative":{"exercise_price":21.66,"expiration_date":"2035-01-15","underlying":"Common Stock","underlying_shares":370000},"source":{"system":"sec-edgar","filing":"0001636282-25-000008","document":"wk-form4_1737149707.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000008/wk-form4_1737149707.xml","form_type":"4"}},{"id":1632598,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-21T02:21:33.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":400,"price":9.82,"value":3928.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":746907,"source":{"system":"sec-edgar","filing":"0000950170-24-017494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024017494/ownership.xml","form_type":"4"}},{"id":1660697,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-03T01:31:10.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":277750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 277,750 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":277750,"derivative":{"exercise_price":25.86,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":277750},"source":{"system":"sec-edgar","filing":"0000950170-24-010904","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017024010904/ownership.xml","form_type":"4"}},{"id":1729352,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Preferred Stock","published_at":"2023-11-27T21:25:02.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":18086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":723440},"source":{"system":"sec-edgar","filing":"0000950170-23-066131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023066131/ownership.xml","form_type":"4"}},{"id":1729351,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-27T21:25:02.000Z","date":"2023-11-22","kind":"grant","planned":false,"acquired":true,"shares":374000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date."}],"balance_after":374000,"derivative":{"exercise_price":10.39,"expiration_date":"2033-11-22","underlying":"Common Stock","underlying_shares":374000},"source":{"system":"sec-edgar","filing":"0000950170-23-066131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023066131/ownership.xml","form_type":"4"}},{"id":1729350,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-27T21:25:02.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":723440,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":746507,"source":{"system":"sec-edgar","filing":"0000950170-23-066131","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636282/000095017023066131/ownership.xml","form_type":"4"}},{"id":2892217,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:15:48.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":53157,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The option vests over four years after November 5, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests over four years after November 5, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":13.2,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":53157},"source":{"system":"sec-edgar","filing":"0000899243-21-003649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003649/doc4.xml","form_type":"4"}},{"id":2892216,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-28T19:15:48.000Z","date":"2021-01-26","kind":"disposition_to_issuer","acquired":false,"shares":9469,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The option vests over four years after June 18, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests over four years after June 18, 2018.  At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85.  Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":9469},"source":{"system":"sec-edgar","filing":"0000899243-21-003649","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003649/doc4.xml","form_type":"4"}},{"id":2892215,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-01-28T19:15:48.000Z","date":"2021-01-26","kind":"other","acquired":false,"shares":50699,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 78 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the \"Merger Agreement\"), by and among the Issuer, BridgeBio Pharma, Inc. (\"Parent\"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub II\"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the \"Effective Time\"). At the Effective Time, each share of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-003649","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924321003649/doc4.xml","form_type":"4"}},{"id":2930273,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":56042,"derivative":{"exercise_price":0.16,"exercise_date":"2020-05-19","expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930272,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":31766,"derivative":{"exercise_price":0.34,"exercise_date":"2020-05-19","expiration_date":"2029-07-14","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930271,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":255500,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930270,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":8563,"price":69.9352,"value":598855.1176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $69.73 to $70.52 per share."}],"balance_after":12568,"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930269,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"sale","acquired":false,"shares":10937,"price":69.3361,"value":758328.9257,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $68.73 to $69.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":21131,"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930268,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":6000,"price":0.16,"value":960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":32068,"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930267,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":6000,"price":0.34,"value":2040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":26068,"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2930266,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-12-30T02:14:53.000Z","date":"2020-12-28","kind":"exercise","acquired":true,"shares":7500,"price":17,"value":127500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":20068,"source":{"system":"sec-edgar","filing":"0000899243-20-035444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320035444/doc4.xml","form_type":"4"}},{"id":2942815,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":21843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments following June 18, 2018, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":53157,"derivative":{"exercise_price":13.2,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":21843},"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942814,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":4451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":9469,"derivative":{"exercise_price":17,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":4451},"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942813,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":3493,"price":112.9657,"value":394589.1901,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $112.73 to $113.59 per share."}],"balance_after":50621,"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942812,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":11445,"price":112.1903,"value":1284017.9835,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $111.73 to $112.72 per share."}],"balance_after":54114,"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942811,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":7600,"price":111.3075,"value":845937.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $110.73 to $111.71 per share."}],"balance_after":65559,"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942810,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"sale","acquired":false,"shares":3756,"price":110.2906,"value":414251.4936,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $109.71 to $110.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 4."}],"balance_after":73159,"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942809,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":21843,"price":13.2,"value":288327.6,"ownership":{"direct":true},"balance_after":76915,"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2942808,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-12-16T19:27:57.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":4451,"price":17,"value":75667.0,"ownership":{"direct":true},"balance_after":55072,"source":{"system":"sec-edgar","filing":"0000899243-20-034181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320034181/doc4.xml","form_type":"4"}},{"id":2966301,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-26T02:54:46.000Z","date":"2020-11-25","kind":"exercise","acquired":false,"shares":742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":263000,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":742},"source":{"system":"sec-edgar","filing":"0000899243-20-032234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032234/doc4.xml","form_type":"4"}},{"id":2966300,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-26T02:54:46.000Z","date":"2020-11-24","kind":"exercise","acquired":false,"shares":4258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":263742,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":4258},"source":{"system":"sec-edgar","filing":"0000899243-20-032234","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032234/doc4.xml","form_type":"4"}},{"id":2966299,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-26T02:54:46.000Z","date":"2020-11-25","kind":"sale","acquired":false,"shares":742,"price":47.2288,"value":35043.7696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $47.03 to $47.32 per share."}],"balance_after":12568,"source":{"system":"sec-edgar","filing":"0000899243-20-032234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032234/doc4.xml","form_type":"4"}},{"id":2966298,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-26T02:54:46.000Z","date":"2020-11-25","kind":"exercise","acquired":true,"shares":742,"price":17,"value":12614.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":13310,"source":{"system":"sec-edgar","filing":"0000899243-20-032234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032234/doc4.xml","form_type":"4"}},{"id":2966297,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-26T02:54:46.000Z","date":"2020-11-24","kind":"sale","acquired":false,"shares":4258,"price":47.0026,"value":200137.0708,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $47.00 to $47.04 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":12568,"source":{"system":"sec-edgar","filing":"0000899243-20-032234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032234/doc4.xml","form_type":"4"}},{"id":2966296,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-26T02:54:46.000Z","date":"2020-11-24","kind":"exercise","acquired":true,"shares":4258,"price":17,"value":72386.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":16826,"source":{"system":"sec-edgar","filing":"0000899243-20-032234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320032234/doc4.xml","form_type":"4"}},{"id":2981513,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-13T17:00:27.000Z","date":"2020-11-11","kind":"gift","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50621,"source":{"system":"sec-edgar","filing":"0000899243-20-031006","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320031006/doc4.xml","form_type":"4"}},{"id":2981512,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-13T17:00:27.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":908,"price":75.2286,"value":68307.5688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $75.19 to $75.27 per share."}],"balance_after":52121,"source":{"system":"sec-edgar","filing":"0000899243-20-031006","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320031006/doc4.xml","form_type":"4"}},{"id":2981511,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-13T17:00:27.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":9497,"price":74.7457,"value":709859.9129,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $74.145 to $75.13 per share."}],"balance_after":53029,"source":{"system":"sec-edgar","filing":"0000899243-20-031006","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320031006/doc4.xml","form_type":"4"}},{"id":2981510,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-13T17:00:27.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":3005,"price":73.564,"value":221059.82,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $73.08 to $74.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 3."}],"balance_after":62526,"source":{"system":"sec-edgar","filing":"0000899243-20-031006","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320031006/doc4.xml","form_type":"4"}},{"id":2988353,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-09T21:05:09.000Z","date":"2020-11-05","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":268000,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-030623","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030623/doc4.xml","form_type":"4"}},{"id":2988352,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-09T21:05:09.000Z","date":"2020-11-05","kind":"sale","acquired":false,"shares":2500,"price":42.0499,"value":105124.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $42.00 to $42.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12568,"source":{"system":"sec-edgar","filing":"0000899243-20-030623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030623/doc4.xml","form_type":"4"}},{"id":2988351,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-11-09T21:05:09.000Z","date":"2020-11-05","kind":"exercise","acquired":true,"shares":2500,"price":17,"value":42500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":15068,"source":{"system":"sec-edgar","filing":"0000899243-20-030623","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320030623/doc4.xml","form_type":"4"}},{"id":2994920,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments following June 18, 2018, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":13920,"derivative":{"exercise_price":17,"expiration_date":"2028-06-20","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":2994919,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":13.2,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":2994918,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":209,"price":72.0961,"value":15068.0849,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $72.01 to $72.13 per share."}],"balance_after":65531,"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":2994917,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":3146,"price":71.4167,"value":224676.9382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $70.98 to $71.94 per share."}],"balance_after":65740,"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":2994916,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":9145,"price":70.4438,"value":644208.551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $69.97 to $70.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 through 4."}],"balance_after":68886,"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":2994915,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":2500,"price":17,"value":42500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":78031,"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":2994914,"issuer":{"id":143355,"kind":"organization","name":"Eidos Therapeutics, Inc.","symbol":"EIDX"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-11-03T16:05:15.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":5000,"price":13.2,"value":66000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":75531,"source":{"system":"sec-edgar","filing":"0000899243-20-030216","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731831/000089924320030216/doc4.xml","form_type":"4"}},{"id":3016508,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":37766,"derivative":{"exercise_price":0.34,"exercise_date":"2020-05-19","expiration_date":"2029-07-14","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016507,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"exercise","acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":62042,"derivative":{"exercise_price":0.16,"exercise_date":"2020-05-19","expiration_date":"2029-05-23","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016506,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":270500,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016505,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"sale","acquired":false,"shares":2058,"price":38.2444,"value":78706.9752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $38.06 to $38.39 per share."}],"balance_after":12568,"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016504,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"sale","acquired":false,"shares":12442,"price":37.5945,"value":467750.769,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $37.00 to $37.99 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3."}],"balance_after":14626,"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016503,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"exercise","acquired":true,"shares":6000,"price":0.34,"value":2040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":27068,"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016502,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"exercise","acquired":true,"shares":6000,"price":0.16,"value":960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":21068,"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3016501,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-02T23:57:52.000Z","date":"2020-09-30","kind":"exercise","acquired":true,"shares":2500,"price":17,"value":42500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":15068,"source":{"system":"sec-edgar","filing":"0000899243-20-026978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320026978/doc4.xml","form_type":"4"}},{"id":3025067,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-22T23:07:46.000Z","date":"2020-09-18","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":273000,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-025962","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320025962/doc4.xml","form_type":"4"}},{"id":3025066,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-22T23:07:46.000Z","date":"2020-09-18","kind":"sale","acquired":false,"shares":2500,"price":42.0097,"value":105024.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $42.00 to $42.06 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":12568,"source":{"system":"sec-edgar","filing":"0000899243-20-025962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320025962/doc4.xml","form_type":"4"}},{"id":3025065,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-09-22T23:07:46.000Z","date":"2020-09-18","kind":"exercise","acquired":true,"shares":2500,"price":17,"value":42500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."}],"balance_after":15068,"source":{"system":"sec-edgar","filing":"0000899243-20-025962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320025962/doc4.xml","form_type":"4"}},{"id":3030374,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":2650,"kind":"person","name":"Turtle Cameron","position":1,"cik":"0001758363","reported_name":"Turtle Cameron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-16T22:38:35.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":275500,"derivative":{"exercise_price":17,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-025366","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320025366/doc4.xml","form_type":"4"}}],"next_cursor":"2020-09-16T22:38:35.000000Z,3030374"}